Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Biologic Trials

Connecticut

Colorectal cancer biologic therapy trials in Connecticut

5 colorectal cancer biologic therapy studies are recruiting participants at sites in 1 city across Connecticut as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 413-6546
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Connecticut city with a recruiting study

New Haven (5).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Connecticut

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Recruiting in
    New Haven
    Registry record
    NCT06662786 · updated
  2. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Recruiting in
    New Haven
    Registry record
    NCT05433142 · updated
  3. A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Recruiting in
    New Haven
    Registry record
    NCT07079631 · updated
  4. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Recruiting in
    New Haven
    Registry record
    NCT05855200 · updated
  5. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GV20 Therapeutics
    Recruiting in
    New Haven
    Registry record
    NCT05669430 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Connecticut on ClinicalTrials.gov.

Ask about studies in Connecticut

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Colorectal Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 413-6546

or send a short form

How should we reach you?

Call